Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Costs and expenses: | ||||
| Cost of goods sold | 199,017 | 206,273 | 373,953 | 394,494 |
| Research and development | 24,253 | 26,997 | 47,754 | 51,725 |
| Selling, general and administrative | 172,436 | 179,890 | 350,671 | 361,387 |
| Intangible asset amortization | 3,770 | 3,754 | 7,546 | 7,458 |
| Goodwill impairment charge | — | 511,365 | — | 511,365 |
| Total costs and expenses | 399,476 | 928,279 | 779,924 | 1,326,429 |
| Operating income (loss) | 19,285 | (512,674) | 30,755 | (528,171) |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's SG&A?
- Integra LifeSciences (IART) reported SG&A of $172.44M in Q2 2026.
- How has Integra LifeSciences's SG&A changed year-over-year?
- Integra LifeSciences's SG&A decreased by 4.1% year-over-year, from $179.89M to $172.44M.
- What is the long-term trend for Integra LifeSciences's SG&A?
- Over 4 years (2021 to 2025), Integra LifeSciences's SG&A has grown at a 2.4% compound annual growth rate (CAGR), from $637.45M to $699.7M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Integra LifeSciences's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude